Navigation Links
Immunosuppressant further linked to birth defects
Date:2/6/2008

A new study documents malformations seen in an infant born to a kidney transplant recipient who had taken mycophenolate mofetil (MMF), a widely used immunosuppressant available commercially as Cellcept. The findings suggest a specific birth defect pattern particular to this drug, reinforcing its potential to harm to the fetus. The study was published in the January 2008 issue of the American Journal of Medical Genetics, available online via Wiley InterScience at http://www3.interscience.wiley.com/journal/117869018/issue.

Approximately 14,000 births to organ transplant recipients, primarily kidney transplant patients, have been reported worldwide. Although pregnancy was initially ill-advised for these women, the American Society of Transplantation concluded in 2003 that pregnancy is usually safe following the first year of a transplant, provided that organ rejection or other complications have not occurred. The fetal side-effects of several immunosuppressant drugs have been studied, though not for widely used newer medications, such as (MMF).

The use of immunosuppressant drugs is a required, life-long treatment for solid organ transplant recipients. They are used to prevent, inhibit or reduce the natural reaction of the immune system against foreign tissues. However, these drugs have important side effects that sometimes preclude their use. The FDA divides immunosuppressants into four categories (A, B, C and D) regarding toxicity to the fetus. MMF has recently been upgraded to class D during pregnancy, meaning that its use is precluded for the high risk of fetal malformations. Immunosupressants are also given to women with severe autoimmune diseases, such as generalized lupus. In fact, 3 out of 10 babies described in the literature regarding these defects had mothers on MMF because of lupus nephritis.

Led by Dr. Antonio Perez-Aytes and Dr. Maximo Vento of the New
'/>"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
Source:Eurekalert

Page: 1 2

Related biology news :

1. Further development of Water Framework Directive necessary
2. Further breakthroughs for breast cancer patients
3. Worlds largest investor coalition seeks further disclosure on climate change and shareholder value
4. Risk of common vaginal infection linked to preterm birth appears higher for blacks
5. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
6. Protein chatter linked to cancer activation
7. Western diet linked to increased risk of colon cancer recurrence
8. Sugary drinks, not fruit juice, may be linked to insulin
9. Brains timing linked with timescales of the natural visual world
10. Low vitamin D during pregnancy linked to pre-eclampsia
11. Genetic variant linked to odor perception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
(Date:7/11/2014)... 2014 The increased risk of kidney injury related ... fluids reflects the mass of HES molecules, according to ... journal of the International Anesthesia Research Society (IARS). , ... effect of HES on cultured human renal proximal tubule ... Wunder and colleagues of University Hospital Wrzburg, Austria. ...
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... Research explains the American obesity paradox: the parallel rise in ... series of four studies, the researchers reveal that we over-generalize ... desserts containing up to 131% more calories when the main ... white view, most food is good or not good, explain ...
... priorities can drive local waste partnerships towards the achievement ... sustainable waste management objectives, a study funded by the ... of waste and disposing of it in environmentally acceptable ... other areas of public service delivery, partnership working is ...
... to tinker with a single amino acid of an ... according to molecular biologists who say the discovery could ... of making vaccines. "We have successfully tested this technique ... of biochemistry and molecular biology at Penn State. "And ...
Cached Biology News:You're likely to order more calories at a 'healthy' restaurant 2Central targets may hinder wider waste management objectives 2Central targets may hinder wider waste management objectives 3Discovery may help defang viruses 2Discovery may help defang viruses 3
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
(Date:7/10/2014)... CROWN POINT, Ind. , July 10, ... recently expanded its use of capnography for ... a growing group of healthcare leaders in ... Capnography measures how effectively patients are breathing ... respiratory depression occurs. By measuring the amount ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today that ... (EMEA) for ranolazine for,the treatment of patients with chronic ... approval follows a positive opinion from the EMEA,Committee for ... 2008., Ranolazine is approved for use in Europe ...
... 10 Quest Diagnostics,Incorporated (NYSE: DGX ), the ... today that its second-quarter,2008 results will be made public ... it will hold its quarterly conference call with investors,to ... that day., The public may access the conference ...
... ALXN ), today announced that the Company will,conduct ... July 29, 2008, at,10:00 a.m. Eastern Time (ET), in ... second quarter ended June 30, 2008. Alexion,anticipates releasing its ... 2008., To participate in this conference call, dial ...
Cached Biology Technology:CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 2CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 3Quest Diagnostics to Release Second Quarter 2008 Financial Results 2
20X TE buffer *RNase free*...
Sheep Serum US Origin...
Human LAIR2 Biotinylated Affinity Purified PAb...
... Lacks the mycobacteria found in Complete ... this reason, Incomplete, Freund's Adjuvant ... may be used to produce water-in-oil emulsions of ... high and long-lasting antibody responses which can be ...
Biology Products: